BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 12402315)

  • 1. Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against Her-2/neu antigen.
    Kim KM; Shin EY; Moon JH; Heo TH; Lee JY; Chung Y; Lee YJ; Cho HM; Shin SU; Kang CY
    Int J Cancer; 2002 Dec; 102(4):428-34. PubMed ID: 12402315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA; Link VC; Greene MI
    Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
    Spiridon CI; Ghetie MA; Uhr J; Marches R; Li JL; Shen GL; Vitetta ES
    Clin Cancer Res; 2002 Jun; 8(6):1720-30. PubMed ID: 12060609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.
    Masui H; Moroyama T; Mendelsohn J
    Cancer Res; 1986 Nov; 46(11):5592-8. PubMed ID: 3756906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu.
    Jasinska J; Wagner S; Radauer C; Sedivy R; Brodowicz T; Wiltschke C; Breiteneder H; Pehamberger H; Scheiner O; Wiedermann U; Zielinski CC
    Int J Cancer; 2003 Dec; 107(6):976-83. PubMed ID: 14601058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
    Mohanty K; Saha A; Pal S; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Breast Cancer Res Treat; 2007 Jul; 104(1):1-11. PubMed ID: 17004107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two distinct mechanisms of antitumor activity mediated by the combination of interleukin 2 and monoclonal antibodies.
    Vuist WM; van Buitenen F; Hekman A; Melief CJ
    Cancer Res; 1990 Sep; 50(18):5767-72. PubMed ID: 1697500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
    Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y
    Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu.
    Baral R; Sherrat A; Das R; Foon KA; Bhattacharya-Chatterjee M
    Int J Cancer; 2001 Apr; 92(1):88-95. PubMed ID: 11279611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model.
    Hooijberg E; van den Berk PC; Sein JJ; Wijdenes J; Hart AA; de Boer RW; Melief CJ; Hekman A
    Cancer Res; 1995 Feb; 55(4):840-6. PubMed ID: 7531616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional properties and effect on growth suppression of human neuroblastoma tumors by isotype switch variants of monoclonal antiganglioside GD2 antibody 14.18.
    Mujoo K; Kipps TJ; Yang HM; Cheresh DA; Wargalla U; Sander DJ; Reisfeld RA
    Cancer Res; 1989 Jun; 49(11):2857-61. PubMed ID: 2720646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens.
    Dhein J; Daniel PT; Trauth BC; Oehm A; Möller P; Krammer PH
    J Immunol; 1992 Nov; 149(10):3166-73. PubMed ID: 1431095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of Her-2/neu vaccine utilizing idiotypic network cascade.
    Pal S; Saha A; Mohanty K; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Cancer Biol Ther; 2007 Dec; 6(12):1916-25. PubMed ID: 18059165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice.
    Schlesinger JJ; Foltzer M; Chapman S
    Virology; 1993 Jan; 192(1):132-41. PubMed ID: 8517015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies.
    Spiridon CI; Guinn S; Vitetta ES
    Clin Cancer Res; 2004 May; 10(10):3542-51. PubMed ID: 15161714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.
    Kaminski MS; Kitamura K; Maloney DG; Campbell MJ; Levy R
    J Immunol; 1986 Feb; 136(3):1123-30. PubMed ID: 3484499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor effect of new HER2 peptide vaccination based on B cell epitope.
    Miyako H; Kametani Y; Katano I; Ito R; Tsuda B; Furukawa A; Saito Y; Ishikawa D; Ogino K; Sasaki S; Imai K; Habu S; Makuuchi H; Tokuda Y
    Anticancer Res; 2011 Oct; 31(10):3361-8. PubMed ID: 21965747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo.
    Drebin JA; Link VC; Greene MI
    Oncogene; 1988 Mar; 2(3):273-7. PubMed ID: 2451200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.